Exploring Depression in Alzheimer's Disease: an Italian Delphi Consensus on Phenomenology, Diagnosis, and Management

Overview

Journal Neurol Sci

Specialty Neurology

Date 2023 Jul 4

PMID 37402937

Authors

Alessandro Padovani

Angelo Antonini

Paolo Barone

Giuseppe Bellelli

Andrea Fagiolini

Luigi Ferini Strambi

Sandro Sorbi

Fabrizio Stocchi

Affiliations

Soon will be listed here.

Abstract

Background: In Alzheimer's disease (AD), the progressive cognitive impairment is often combined with a variety of neuropsychiatric symptoms, firstly depression. Nevertheless, its diagnosis and management is difficult, since specific diagnostic criteria and guidelines for treatment are still lacking. The aim of this Delphi study is to reach a shared point of view among different Italian specialists on depression in AD.

Methods: An online Delphi survey with 30 questions regarding epidemiology, diagnosis, clinical features, and treatment of depression in AD was administered anonymously to a panel of 53 expert clinicians.

Results: Consensus was achieved in most cases (86%). In the 80% of statements, a positive consensus was reached, while in 6% a negative consensus was achieved. No consensus was obtained in 14%. Among the most relevant findings, the link between depression and AD is believed to be strong and concerns etiopathogenesis and phenomenology. Further, depression in AD seems to have specific features compared to major depressive disorder (MDD). Regarding diagnosis, the DSM 5 diagnostic criteria for MDD seems to be not able to detect the specific aspects of depression in AD. Concerning treatment, antidepressant drugs are generally considered the main option for depression in dementia, according to previous guidelines. In order to limit side effects, multimodal and SSRI antidepressant are preferred by clinicians. In particular, the procognitive effect of vortioxetine seems to be appealing for the treatment of depression in AD.

Conclusions: This study highlights some crucial aspects of depression in AD, but more investigations and specific recommendations are needed.

Citing Articles

Decoding Alzheimer's Disease With Depression: Molecular Insights and Therapeutic Target.

Li Z, Guo H, Ge Y, Li X, Dong F, Zhang F J Cell Mol Med. 2025; 29(5):e70454.

PMID: 40074694 PMC: 11903198. DOI: 10.1111/jcmm.70454.

Decreased prefrontal activation during verbal fluency task after repetitive transcranial magnetic stimulation treatment for depression in Alzheimer's disease: a functional near-infrared spectroscopy study.

Zhao Y, Qiu C, Lin P, Yang M, Huang L, Zhao Z Front Aging Neurosci. 2025; 16():1460853.

PMID: 39845447 PMC: 11751059. DOI: 10.3389/fnagi.2024.1460853.

Use of vortioxetine in different neurological fields: a systematic review and future perspectives.

Verrienti G, Colonna I, Raccagni C Neurol Sci. 2025; .

PMID: 39808348 DOI: 10.1007/s10072-025-07987-1.

Changes in dementia treatment patterns associated with changes in the National Policy in South Korea among patients with newly diagnosed Alzheimer's disease between 2011 and 2017: results from the multicenter, retrospective CAPTAIN study.

Kim Y, So K, Lee H, Hahn C, Song S, Lee Y BMC Public Health. 2024; 24(1):168.

PMID: 38216922 PMC: 10787419. DOI: 10.1186/s12889-024-17671-2.

Depression and Pseudodementia: Decoding the Intricate Bonds in an Italian Outpatient Setting.

Buccianelli B, Marazziti D, Arone A, Palermo S, Simoncini M, Carbone M Brain Sci. 2023; 13(8).

PMID: 37626556 PMC: 10452733. DOI: 10.3390/brainsci13081200.

References

Spranger J, Homberg A, Sonnberger M, Niederberger M . Reporting guidelines for Delphi techniques in health sciences: A methodological review. Z Evid Fortbild Qual Gesundhwes. 2022; 172:1-11. DOI: 10.1016/j.zefq.2022.04.025. View

Finkel S, Costa E Silva J, Cohen G, Miller S, Sartorius N . Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8 Suppl 3:497-500. DOI: 10.1017/s1041610297003943. View

DAgostino A, English C, Rey J . Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015; 40(1):36-40. PMC: 4296590. View

McIntyre R, Lophaven S, Olsen C . A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014; 17(10):1557-67. PMC: 4162519. DOI: 10.1017/S1461145714000546. View

Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S . Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. Dement Geriatr Cogn Disord. 2008; 25(6):559-63. DOI: 10.1159/000137671. View

Diniz B, Butters M, Albert S, Dew M, Reynolds 3rd C . Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry. 2013; 202(5):329-35. PMC: 3640214. DOI: 10.1192/bjp.bp.112.118307. View

Goodarzi Z, Mele B, Guo S, Hanson H, Jette N, Patten S . Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurol. 2016; 16(1):244. PMC: 5124305. DOI: 10.1186/s12883-016-0754-5. View

Reitz C, Mayeux R . Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014; 88(4):640-51. PMC: 3992261. DOI: 10.1016/j.bcp.2013.12.024. View

Gainotti G, Marra C . Some aspects of memory disorders clearly distinguish dementia of the Alzheimer's type from depressive pseudo-dementia. J Clin Exp Neuropsychol. 1994; 16(1):65-78. DOI: 10.1080/01688639408402617. View

10.

Asmer M, Kirkham J, Newton H, Ismail Z, Elbayoumi H, Leung R . Meta-Analysis of the Prevalence of Major Depressive Disorder Among Older Adults With Dementia. J Clin Psychiatry. 2018; 79(5). DOI: 10.4088/JCP.17r11772. View

11.

Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J . Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011; 343:d4551. PMC: 3149102. DOI: 10.1136/bmj.d4551. View

12.

Ownby R, Crocco E, Acevedo A, John V, Loewenstein D . Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006; 63(5):530-8. PMC: 3530614. DOI: 10.1001/archpsyc.63.5.530. View

13.

Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P . Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2003; 14(4):389-404. DOI: 10.1017/s104161020200858x. View

14.

Ismail Z, Elbayoumi H, Fischer C, Hogan D, Millikin C, Schweizer T . Prevalence of Depression in Patients With Mild Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2016; 74(1):58-67. DOI: 10.1001/jamapsychiatry.2016.3162. View

15.

Pakaski M, Bjelik A, Hugyecz M, Kasa P, Janka Z, Kalman J . Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. Neurochem Int. 2005; 47(3):190-5. DOI: 10.1016/j.neuint.2005.03.004. View

16.

Gibson C, Goeman D, Yates M, Pond D . Clinical practice guidelines and principles of care for people with dementia: a protocol for undertaking a Delphi technique to identify the recommendations relevant to primary care nurses in the delivery of person-centred dementia care. BMJ Open. 2021; 11(5):e044843. PMC: 8126272. DOI: 10.1136/bmjopen-2020-044843. View

17.

Barnes D, Yaffe K, Byers A, McCormick M, Schaefer C, Whitmer R . Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry. 2012; 69(5):493-8. PMC: 3704214. DOI: 10.1001/archgenpsychiatry.2011.1481. View

18.

Kessing L, Harhoff M, Andersen P . Treatment with antidepressants in patients with dementia--a nationwide register-based study. Int Psychogeriatr. 2006; 19(5):902-13. DOI: 10.1017/S1041610206004376. View

19.

Herrmann N, Rabheru K, Wang J, Binder C . Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005; 13(6):527-34. DOI: 10.1176/appi.ajgp.13.6.527. View

20.

Rosler M, Retz W, Retz-Junginger P, Dennler H . Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 2001; 11(4):211-216. DOI: 10.1155/1999/168023. View